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Background: Preclinical evaluation of the anti-neoplastic activity of antisense oligonucleotide (AS) suppression of
human insulin-like growth factor I receptor (IGF-IR) in human epithelial ovarian cancer (EOC).
Methods: Ovarian cancer cells from 36 patients with EOC were investigated under serum-free tissue culture
conditions. IGF-I production was evaluated by standard ELISA. IGF-IR and phosphorylated IRS-1, AKT, and MAP
kinase expression and protein levels were evaluated by immunohistochemistry and Western blotting. Cancer cell
growth and proliferation assays were performed in triplicates using MTT assay. Apoptosis was evaluated by
TUNNEL assay.
Results: All ovarian cancer tissue samples tested produced IGF-I and expressed IGF-IR, supporting the existence
of an autocrine loop. Treatment of primary ovarian cancer cell lines with an IGF-1R AS inhibited growth and
proliferation and decreased clonogenicity in soft agar assay. AS treatment was demonstrated to inhibit the
expression of IGF-1R and decrease the concentration of phosphorylated IRS-1, AKT, and MAP kinase signaling
protein downstream of the IGF-IR. We also observed that the IGF-1R AS sensitized cancer cell lines to cisplatin
in vitro through the PI3K pathway.
Conclusions: IGF-IR enhances the proliferation and tumorigenicity of human ovarian cancer cells and inhibition of
IGF-IR by AS oligonucleotide treatment potentiates the activity of cisplatin in vitro. Therefore, IGF-1R is a potential
molecular target in ovarian cancer.
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Epithelial ovarian cancer (EOC) constitutes 90% of ova-
rian malignancies and is the most lethal gynecological
malignancy. Although most EOC patients experience a
reasonable initial clinical response to debulking surgery
and chemotherapy, the majority of these patients will
not be cured [1-3]. Approximately 70% of EOC patients
will experience EOC recurrence and chemoresistance is
responsible for the majority of ovarian cancer-related
deaths [1,4,5]. Current treatments are incapable of
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reproduction in any medium, provided the orevolution into chemoresistant disease. Therefore, new
therapeutic modalities are urgently needed to overcome
chemoresistance in EOC. Accumulating evidence sug-
gests that the insulin like growth factor (IGF) pathway
may be a good therapeutic target in several cancer types,
including ovarian cancer [5-7]. In this paper, we will
focus on the role of IGF-1R in ovarian cancer tumori-
genesis and treatment.
IGF ligands, receptors and IGF binding proteins
(IGFBPs) have been shown to play a critical role in the
development and progression of human cancers [5,8,9].
IGFBPs are a family of six homologous proteins with
high binding affinity for IGF-I and IGF-II. All six IGFBPs
have been shown to inhibit IGF action, but stimula-
tory effects have also been established for IGFBP-1, -3,
and -5 [10]. Elevated plasma concentrations of IGF-1 ord. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical/pathological characteristics of the
patients a (n=36)
Characteristic Number (%)





Optimal (≤1 cm) 24(66%)








aAll patients received standard adjuvant platinum/taxane-based chemotherapy.
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cers, including breast, prostate and lung cancer [11-13].
In addition, IGF-1/IGF-IR has been studied extensively
in metastatic colon, pancreatic, prostate and breast can-
cer [14,15]. In many human cancers, there is a strong as-
sociation between dysregulation of the IGF signaling
pathway and cancer risk that has been extensively inves-
tigated [7,15-17]. In contrast to other epithelial malig-
nancies, limited data are available on the potential role
of the IGF-1R in EOC [18].
Yee et al. identified expression of IGF-I mRNA in 3 of
10 ovarian cancer cell lines (OVCAR-3, OVCAR-7 and
PEO4) and ovarian cancer tissue specimens [5]. They
also reported expression of several IGFBPs and IGF-IR
by ovarian cancer cells. This study suggested that all
necessary components for an IGF-I-mediated autocrine
loop are present in ovarian cancer cells, an observation
that was confirmed in an early study using the OVCAR-3
cell line [17]. During the same period, it was reported that
IGF-I level was higher in cyst fluid from invasive malig-
nant neoplasms compared to benign tumors [17]. Later,
another group confirmed the presence of IGF-IR expres-
sion by immunohistochemistry (IHC) in 100% of the ovar-
ian carcinoma samples tested [6]. These initial studies
opened the door to further research in ovarian cancer,
indicating an involvement of the IGF system in ovarian
tumorigenesis [11,14,15,19]. Moreover, Brokaw et al.
showed that high free IGF-I protein expression in ovarian
tumor tissue was independently associated with the pro-
gression of ovarian cancer [19]. IGF-I mRNA expression
was also associated with disease progression, implying that
both endocrine and paracrine/autocrine regulations of
IGF-I activity are involved in ovarian cancer [6,20]. Simi-
larly, microarray expression profiles from 64 EOC patients
demonstrated that individual genes, including IGF-I,
IGF-IR and several genes downstream of the receptor,
were over-expressed in tumors associated with an un-
favorable prognosis [21].
The strategies to target IGF-1 system in cancer consist
of [1] reducing circulating ligand levels or bioactivity
[2,22] blocking receptor function using receptor-specific
antibodies or small-molecule tyrosine kinase inhibitors
[1,23,24] and [3] activating AMP-activated protein kin-
ase (AMPK) [25]. In the past few years, various inhibi-
tors of IGF-IR have been developed, including AMPK
activators [26]. In vivo studies have expanded the un-
derstanding of the IGF-1 system and its therapeutic po-
tential in cancer; however, in vitro results have been
inconclusive and further study is needed to more pre-
cisely determine the therapeutic significance of these
findings.
In this study, through an in vitro culture system as an
experimental model we used tumor specimens and pri-
mary ovarian cancer cells from patients with advanced-stage epithelial ovarian cancer to comprehensively ana-
lyze the possibility that IGF-1R is important in regu-
lating the autocrine growth of ovarian cancer cells. We
report that the ovarian cancer cells from patients with
advanced EOC produce endogenous IGF-1, express IGF-
1R and grow autonomously in serum-free media (SFM).
Their growth in these conditions, however, is further
stimulated by the addition of IGF-1. Treatment with
IGF-1R mRNA antisense oligodeoxynucleotides (AS)
markedly inhibits the proliferation of these cells in SFM
in the presence of IGF-1. This inhibition corresponds to
a reduction in the amount of detectable IGF-1R. These
data together suggest that the IGF-1/IGF-1R system may
have a prominent role in the proliferation of EOC cells.
The results also support another function of the IGF-1R
to protect cancer cells from apoptosis. We also observed
that IGF-1R AS sensitized cells to cisplatin in vitro.
Methods
Patient and tumor samples
The study population consisted of 36 patients with ad-
vanced EOC (International Federation of Gynecology
and Obstetrics, FIGO stage III/IV) from Hunan Provin-
cial Tumor Hospital, diagnosed between 2007 and 2008.
The characteristics of the patient cohort are described in
Table 1. All patients underwent total abdominal hys-
terectomy and bilateral salpingo-oophorectomy by an
expert gynecologic oncologist according to standard de-
bulking guidelines and all received standard adjuvant plat-
inum/taxane-based chemotherapy. Outpatient follow-up
was regularly performed (median follow-up duration was
3 years). Tissue and clinical data collection was approved
by the Institutional Review Boards in Hunan Provincial
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sent. Ovarian cancer samples were collected at the time of
primary debulking surgery and frozen at −80°C. Staging
was reported according to the FIGO (2009). Optimal
debulking was defined as ≤1 cm gross residual disease,
and suboptimal debulking as more than 1 cm residual dis-
ease. Overall survival (OS) was defined as the time be-
tween the date of diagnosis of ovarian cancer and the date
of death.
Preparation of patient tumor cell lines
Tumor tissue from each patient was cut into small
pieces with a sterile scalpel blade. Tumor fragments
were suspended in 2 mL of a 0.25% Trypsin-EDTA solu-
tion (Gibco-BRL, Grand Island, NY) and pipetted up
and down to break up large tissue fragments. After incu-
bation for 5 minutes at 37°C, the suspension was again
disaggregated and transferred to a 100 mm Primaria
Petri dish (BD, Franklin Lakes, NJ) containing 10 mL
of RPMI 1640/Opti-MEM (Gibco-BRL) (1:1 ratio) sup-
plemented with 10% fetal bovine serum, 2 mmol/L
glutamine, 100 units/mL of penicillin, and 100 μg/mL
streptomycin. Cell lines were passaged three to four
times before use. Normal epithelial ovarian cells (NEOC)
from 10 patients with benign serous epithelial ovarian
tumor were tested as a normal control. Tumor cells
(109) were harvested, rinsed, re-suspended in 2 mL
HBSS and lysed by five freeze/thaw cycles (dry ice/room
temperature), followed by sonication for 2 minutes at
4°C to break up DNA. Debris was spun down at 400 × g
for 25 minutes, and the supernatant was collected and
stored in aliquots at −80°C. Lysates from normal epithe-
lial ovarian cells were also used as a normal control.
Immunohistochemistry(IHC) staining of EOC tissue
samples
Immunohistochemistry(IHC) was performed to deter-
mine protein expression of IGF-1R in EOC surgical
specimens, using monoclonal antibodies against IGF-1R
(mouse monoclonal, 1:100; NeoMarkers, Fremont, CA,
USA). The slides were then incubated with a goat bio-
tinylated secondary antibody provided in the detection
kit, and horseradish peroxidase agent for 60 min, and in-
cubated with the substrate chromogen 3,3′-diaminoben-
zidine for 5 min. Protein expression levels were assessed
by two experienced pathologists.
Level of total IGF-I in tumor cell lysates and cell culture
medium
A non-extraction IGF-1 enzyme-linked immunosorbent
assay (ELISA) kit (DSL-10-2800) from Diagnostics Sys-
tems Laboratories, Inc., Webster, TX, USA was used for
the determination of IGF-1 level in tumor cell lysate and
cell culture medium. Samples were tested in duplicatesand repeated if the correlation coefficient between the
absorbance and the amount in the standards was less
than 0.95.
Cell growth and proliferation analyses
Cancer cells and normal epithelial ovarian cells were
seeded in medium containing 10% fetal bovine serum, at
an initial density of 3–6 × 103 cells/cm2. The cells were
allowed to attach for 24 h and then arrested in serum
free medium (SFM). After the addition of 20 ng/ml
IGF-1 (Life Technologies, Inc., Gaithersburg, MD), du-
plicate cultures were counted in a hemocytometer at 24,
48 and 72 h. In a successive experiment, normal cells
and cancer cells were tested for growth in SFM without
the addition of IGF-1. Then, cancer cells maintained in
SFM were exposed to an IGF-1R sense oligonucleotide
(5′-AAG TCT GGC TCC GGA GGA) or antisense
(5′-TCC TCC GGA GCC AGA CTT) IGF-1R mRNA
oligodeoxynucleotides (40 ng/ml) for 48 h with and
without the addition of IGF-1. This antisense represents
codons 2-7of the prepropeptide and has been shown
previously to effectively decrease the number of IGF-1
receptors [27]. In this experiment, the cells were coun-
ted using MTT (Sigma Chemical Co., Milwaukee, WI).
This assay is based on reduction of MTT to formazan
by enzymes present only in viable, metabolically active
cells. After exposure to sense or antisense IGF-1R mRNA
oligonucleotides, the medium was removed, and 0.1 ml of
MTT (50 μg) was added to each well. After incubation for
2 h at 37°C, the multiwell plate was centrifuged to pellet
formazan crystals, and the medium was discarded. Then,
0.1 ml of DMSO was added to each well to dissolve the
MTT formazan crystals. The absorbance of formazan at
540 nm was measured by Emax microplate reader. A
mean of 18 replicates cultured from three experiments
were used for statistical analysis.
Western blot analyses
The expression of IGF-1R and phosphorylated IRS-1,
AKT and MAP kinase in cancer cells was analyzed by
Western immunoblotting as follows: cell lysates were
obtained from the above cells exponentially growing in
10% serum. After clarification by centrifugation and pro-
tein concentration determination, 20 μg of protein were
resolved on a 4–15% polyacrylamide gradient gel by
SDS-PAGE and electroblotted into a nitrocellulose filter.
The filter was immunoblotted with mouse anti-human
monoclonal antibodies to identify the IGF-1R α and
phosphorylated IRS-1, AKT and MAP kinase (Life
Technologies, Inc.), followed by secondary horseradish
peroxidase- conjugated horse anti-mouse IgG antibodies
(Oncogene, Science, Inc. Mineola, NY). Antigen bound
to nitrocellulose membrane polyvinylidene difluoride
(PVDF) was detected and protein bands were visualized
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tetrahydrochloride (DAB) substrate.
Apoptosis assays
Apoptosis was determined by TUNEL, using an in-
situ cell-death detection kit (Boehringer Mannheim,
Indianapolis, IN) according to the manufacturer's proto-
col. Briefly, cancer cells were treated with 40 ng/ml anti-
sense IGF-1R mRNA (AS), LY294002, cisplatin or the
combination of these two agents for 48 to 72 hours. After
treatment, cells were trypsinized and cytospin prepara-
tions were obtained. Cells were fixed with freshly prepared
paraformaldehyde [4% in PBS (pH 7.4)], rinsed with PBS,
and incubated in permeabilization solution. After cross-
reaction with TUNEL reaction mixture for 60 min at 37°C
and cross-reaction with converter-alkaline phosphatase
solution for 30 min at 37°C in a humidified chamber, the
slides were reacted with alkaline phosphatase substrate so-
lution for 5–10 min (Vector Laboratories, Burlington,
MA), rinsed and mounted under a coverslip for analysis
with a light microscope. The number of TUNEL-positive
cells was counted in five different fields under a lightFigure 1 Level of IGF-1R and IGF-1 in EOC. (A) IGF-1R expression in surg
pictures of surgical samples with different IGF-1R expression (original magn
epithelial serous ovarian tumor tissues. (b, c) EOC tissues clearly expressed
IGF-1 level in tumor cell lysates and cell culture medium by ELISA. IGF-1 lev
in normal epithelial ovarian cell lysates and cell culture medium(n=10)(P<0microscope at ×40 magnification, and representative fields
were photographed. The percentages of apoptotic cells
were calculated from the ratio of apoptotic cells to total
cells counted. At minimum, 500 cells were counted in five
different fields, and assays were performed in duplicate
three times (×6).
Clonogenicity in soft agar
After exposure to antisense IGF-1R mRNA oligonu-
cleotides (40 ng/ml) for 48 h, cancer cells were seeded at
a density of 6 × 103/35-mm plate in 15% fetal bovine
serum on a top layer of 0.3% agar and a bottom support
layer of 1% agar. The plates were incubated at 37°C.
Colonies of greater than 10 cells were counted 7 and
14 days later. Cancer cells without antisense treatment
were used as a control.
Statistical analyses
Comparisons between case subjects and control subjects
were undertaken by t tests, χ2 tests and 2 independent
samples tests. Differences were considered significant
when P < 0.05.ical specimens of epithelial ovarian cancer (EOC). Representative
ification ×100). (a) IGF-1R protein expression was low in benign
IGF-1R protein. Magnification was in small square. (B) Quantitated
el in tumor cell lysates and cell culture medium is much higher than
.05). [2 independent sample tests].
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Clinical and pathological characteristics
The clinical and pathological characteristics of the 36
patients are shown in Table 1. The median patient age
was 57 years. All patients had advanced-stage disease,
and the majority had grade 3 (80%) or serous (90%)
EOC. After primary surgery, 66% of patients were opti-
mally debulked. The median follow-up interval was
3 years. As of January 2011, 20 patients from the entire
cohort remained alive.
IGF-1R and IGF-1 expression in EOC cells
We examined the expression of IGF-1R in surgical
specimens of epithelial ovarian cancer by IHC. As shown
in Figure 1A-a, IGF-1R protein staining was sparse in
both normal and benign serous epithelial ovarian tumor
tissues in all surgical specimens examined (n=10). In
contrast, IGF-1R staining was significantly increased in
epithelial ovarian cancer tissues (n=36) (Figure 1A-b, c).
All specimens were graded for the distribution of IGF-
1R staining. Low grade indicates that the distribution of
IGF-1R staining is less than 50% of tumor area, whereas
high grade indicates that the distribution of IGF-1R
staining is more than 50% of tumor area. 25 of 36Figure 2 Proliferation characteristics of ovarian cancer cells. Proliferati
medium (SFM) with (A) and without (B) the addition of IGF-1 (20 ng/ml). T
of normal cells (P<0.05). (C) Effect of antisense (AS) IGF-1R mRNA oligonuc
SFM as described in the “Methods” section. AS or sense oligonucleotides (S
IGF-1 (20 ng/ml) at time zero. Cells were counted at the indicated times. Th
three representative experiments.epithelial ovarian cancer tissues expressed IGF-1R with
high grade, and 9 expressed IGF-1R with low grade.
After testing 10 samples from each group using ELISA,
we observed that primary cancer cell lines had consis-
tently higher levels of IGF-1 in both cell lysates and cell
culture medium than normal epithelial ovarian cell lines
(P<0.05) (Figure 1B). The mean level of IGF-1 in cell ly-
sates and cell culture medium was higher among case
subjects (258.2 ng/mL/230 ng/ml) than among control
subjects (118.3 ng/mL/101.9 ng/ml) (P <0.05).
Growth characteristics of ovarian cancer cells
The growth characteristics of cancer cells compared with
normal cells are shown in Figure 2A. When cultured in
SFM, normal cells did not respond to the addition of
exogenous IGF-1. Conversely, the growth response of
cancer cells to IGF-1 was 20-fold greater (P < 0.05). Even
in SFM alone, cancer cells proliferated, although at a
lower rate (8-fold, Figure 2B) (P < 0.05). The addition of
AS against the IGF-1R mRNA decreased cancer cell
growth rate by 70%, both in the presence and absence of
exogenous IGF-1 (Figure 2C) (P < 0.05). We observed
IGF-IR AS growth inhibition of the ovarian cancer cells,
with IC50 between 25 and 30 ng/ml.on of normal cells and cancer cell lines 1, 2, and 3 in serum free
he proliferation of cancer cell lines is approximately 20-fold over that
leotides on the growth of cancer cells. Cancer cells were maintained in
,40 ng/ml) were added to the medium for 24 h before the addition of
e data represent the mean of triplicate determinations from one of
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cells after IGF-IR AS treatment
Ovarian cancer cells exhibited a distinct band of mole-
cular weight 135,000 representative of the α subunit of
the IGF-1R when examined by Western immunoblot-
ting. Conversely, at the same molecular weight normal
epithelial ovarian cells displayed a weak, indistinct band
(Figure 3A). After incubating cancer cells with IGF-IR
AS for 48 hrs in SFM, IGF-1R expression was effectively
inhibited by at 30-50 ng/ml IGF-1R mRNA oligonucleo-
tides (Figure 3B). We observed expression inhibition of
IGF-1R by IGF-IR AS, with IC50 of 30 ng/ml. Interest-
ingly, the IGF-IR AS also variably decreased the expres-
sion of the phosphorylated IRS-1, AKT, and MAP kinase
signaling proteins downstream of IGF-IR (Figure 3C).
Sensitization of ovarian cancer cells to cisplatin by
IGF-IR AS
A TUNEL alkaline phosphatase assay demonstrated that
ovarian cancer cells underwent apoptosis after exposureFigure 3 Effect of antisense IGF-1R mRNA oligonucleotides (AS) on IG
free medium (SFM) as described in the “Methods” section for 24 hrs. Oligon
before cells were harvested for western blotting assay. (A) Western Blotting
epithelial ovarian cells. 1 and 2 represent normal epithelial ovarian cells; 3 a
loading control. (B) AS inhibited IGF1-R expression at different concentratio
control. (C) AS also variably inhibited phosphorylated IRS-1, AKT, and MAP
the loading control.to cisplatin, a first line chemotherapy agent for EOC
(Figure 4A-b). To test whether the observed IGF-1R ac-
tivation plays a role in cisplatin-induced apoptosis, we
selectively inhibited IGF-1R activity by using IGF-IR AS.
Apoptosis was also induced in ovarian cancer cells after
IGF-IR AS treatment (Figure 4A-c). However, 24 hours
pretreatment with 40 ng/ml AS followed by the treat-
ment of 2umol/L cisplatin for 48 hours significantly
increased apoptosis compared to either agent alone
(Figure 4A-d and 4B). These results thus indicate that
the IGF-1R is required for human EOC cells undergo-
ing apoptosis upon cisplatin treatment.
IGF-IR signaling through the PI3K pathway is crucial for
cisplatin resistance
To determine the function of IGF-IR and PI3K signaling
pathways in cisplatin resistance, we used specific in-
hibitors. As shown in Figure 4C, the PI3K inhibitor
LY294002 [28] efficiently sensitized ovarian cancer cells
to cisplatin, similar to IGF-1R AS treatment (Figure 4D).F-1R expression by cancer cells. Cancer cells were arrested in serum
ucleotides at different doses were added to the medium for 48 hrs
showed the cancer cells expressing more IGF-1R than the normal
nd 4 represent epithelial ovarian cancer cells. Actin was used for the
ns in epithelial ovarian cancer cells. Actin was used for the loading
kinase expression in epithelial ovarian cancer cells. Actin was used for
Figure 4 Apoptosis in human ovarian cancer cells was induced by different treatments as revealed by TUNEL assay. (A) Apoptosis was
shown in human oravian cancer cells by TUNEL assay. TUNEL-positive nuclei due to DNA fragmentation (white condensed spots) are indicated by
arrows. (a) Without treatment as a negative control; (b) Treated with cisplatin (Cis) alone; (c) Treated with antisense IGF-1R mRNA oligonucleotide
(AS) alone; (d) Treated with the combination (Cis+AS). (B) There was a significant potentiation in the induction of apoptosis observed in cancer
cells treated with both Cis and AS as compared to cells treated with either agent alone (P<0.05). (C) Effect of IGF-IR (AS) on cisplatin treated
ovarian cancer cells. Ovarian cancer cells were cultivated in the presence of AS and cisplatin. Arrows, IC50 concentrations of cisplatin for AS (left
arrow) and medium control (right arrow). (D) IGF-IR signaling through the PI3K pathway is essential for cisplatin resistance in ovarian cancer cells.
Ovarian cancer cells were cultivated in the presence of cisplatin and LY294002, which inhibits PI3K activity. Arrows, IC50 concentrations of
cisplatin for LY294002 and medium control.
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ERK kinase 1/2 inhibitors U0126 [29] did not affect cis-
platin resistance (data not shown), indicating that the
ERK1/2 signaling pathway is not involved. These results
indicate that IGF-IR dependent signaling through the
PI3K pathway is responsible for cisplatin resistance.Effect of IGF-1R AS on clonogenicity of cancer cells
As described in Methods, each clone was seeded in soft
agar to check the inhibition of anchorage-independent
cell growth by IGF-1R AS. Table 2 and Figure 5 showed
the inhibitory effect of IGF-1R AS on the anchorage-
independent growth of cancer cells. After AS treatment
in 15% serum-rich soft agar, cancer cells produced over10-fold fewer colonies compared to cancer cells without
AS treatment (P < 0.05).
Discussion
There are two main causes for high mortality rate of ad-
vanced ovarian cancer. The first is its tendency to spread
into the abdominal cavity during its early stages. This
intra-abdominal dissemination often makes complete re-
section of the disease quite difficult. The second is its
acquired resistance to platinum-based drugs during cyc-
lic chemotherapy [4,18]. Therefore, it has become essen-
tial to understand the molecular mechanism of ovarian
cancer cell proliferation and growth and introduce new
therapeutic modalities that may benefit these patients.
The present study focuses on the role of IGF-1R in
Table 2 Number of clonies formed in soft sugar
Time Cancer cells w/o AS Cancer cells w AS
Line 1 Line 2 Line 3 Line 1 Line 2 Line 3
1 wk 698 509 759 38 48 68
2 wk 2102 1608 1440 42 57 72
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of IGF-1R AS. The pro-apoptotic function of IGF-1R
might serve as a chemosensitizer, and therefore offers
new insight and opportunity for the development of
novel therapeutic strategies for the treatment of EOC.
In recent years, IGF-1R and its ligand IGF-1 have been
considered not only to be growth factors but also potent
survival factors [14,19,30,31]. IGF-1 is a progression
factor able to bind the IGF-1R with high specificity. The
activation of this receptor induces a cascade of intra-
cellular tyrosine phosphorylations that culminate in the
activation of transcription factors involved in the synthe-
sis of proliferation-inducing proteins [14,30-32]. Under
normal physiological conditions, the expression and acti-
vation of IGF-IR is tightly controlled. In this study using
primary tumor tissue and cancer cells from patients, we
showed striking over-expression of IGF-IR and IGF-1 in
comparison to normal ovarian tissue samples. IGF-1 and
IGF-1R both have been shown to be upregulated in mul-
tiple cancer cell types, affecting proliferation, differenti-
ation, and metastasis. Primary cancer cells from patients
with advanced epithelial ovarian cancer produced en-
dogenous IGF-1, grew autonomously and proliferated inFigure 5 Number of colonies formed by human ovarian cancer cells i
(line1-3) after AS treatment in 15% serum-rich soft agar produced over 10-
treatment (P < 0.05).SFM. Their growth in SFM was further stimulated by
the addition of IGF-1. These data confirm the existence
of a functional autocrine loop in EOC. Treatment with
IGF-1R AS markedly inhibited the proliferation of these
cells both in SFM and in the presence of IGF-1. IGF-1R
AS also inhibited anchorage-independent cell growth
(Table 2, Figure 5). AS-treated ovarian cancer cells
exhibited a corresponding reduction in the amount of
detectable phosphorylated IGF-1R. Taken together, these
data indicate that the IGF-1/IGF-1R system has a pro-
minent role in the proliferation of human epithelial
ovarian cancer cells.
Recent reports have implicated IGF-1R in programmed
cell death [33,34]. The biochemical and molecular as-
pects of apoptosis have recently been delineated [35,36].
Resnicoff et al. have shown that an activated and overex-
pressed IGF-1R has a protective role in apoptosis [34],
and that this function is independent of its mitogenic ac-
tion [37]. There is evidence that cells may escape death
either by an IGF-1R-mediated increase in Bcl-2 and Bcl-
XL, or by a failure of p53 inhibition of mitogenic signaling
by IGF-1R via secretion of IGF-binding proteins [38,39].
Another possibility is that the activation of IGF-1R mo-
dulates changes in the expression of death-inducing sig-
naling complex proteins and/or receptors (MORT/FADD,
MACH/FLICE, FAS, FAP-1,etc.) [8,40,41]. Interestingly,
upon binding of IGF-1 to the IGF-1 receptor, a signaling
cascade is put in motion resulting in increased gene ac-
tivation, cell cycle progression, cell growth, differentiation
and an anti-apoptotic effect. These events follow twon soft agar treated with or without AS. Human ovarian cancer cells
fold fewer colonies as compared to the cancer cells without AS
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feedback loops creating a complex network of communi-
cation within the cell. One pathway is the PI3K/Akt path-
way and the other is the Ras/MAPK pathway [42,43].
Both the PI3K-Akt-mTOR and Raf-MEK-MAPK pathways
are thought to be important downstream signaling path-
ways ultimately leading to activation of mitogenic/anti-
apoptotic transcription factors such as cFos and cJun
[7,39]. Each signaling cascade takes a divergent path with
some cross talk evident. In this study, inhibition of IGF-
1R expression in primary ovarian cancer cells with an
IGF-1R AS induced apoptosis. We tested the effect of the
IGF-1R AS on EOC cells and observed a 35-40% rate of
apoptosis. We found several of these IGF-1R signaling
proteins had altered phosphorylation levels after antisense
treatment in EOC. We measured these signaling proteins
phosphorylation by western blot and observed variable in-
hibition of phosphorylated IRS-1, AKT, and MAP kinase
expression in epithelial ovarian cancer cells by AS. This
suggests that the apoptotic action of IGF-1R AS may
represent the end result of the modulation of IGF-1R-
dependent signaling cascade by decreased expression of
IGF-1R in EOC cells. Additional investigations studying
the interaction between apoptotic and anti-apoptotic sig-
nals should be done to provide new insights into the
pathobiology of EOC.
With respect to drug targets, chemoresistance can also
be triggered by overexpression of receptor tyrosine ki-
nases, including ERB B1-4, IGF-1R, VEGFR 1–3 and
PDGF receptor family members [44-46]. For instance,
ERBB2 (also called HER 2) activates the small G protein
RAS, leading to downstream MAPK signaling and prolif-
eration as well as PI3K/AKT pathway and cell survival
[46]. We hypothesize that IGF-1 and IGF-1R are impor-
tant in the control of chemosensitivity and that their
dysregulation may confer cisplatin chemoresistance in
EOC. We found that rate of apoptosis induced by cis-
platin alone was about 40% by TUNNEL assay. Notably,
inhibition of IGF-1R by AS dramatically increased the
sensitivity of ovarian cancer cells to the chemotherapeu-
tic agent cisplatin compared with either agent alone. We
observed a significant increase in apoptosis (60%) in-
duced by the combination of AS and cisplatin. Our re-
sults indicate that IGF-IR–dependent signaling through
the PI3K pathway mediates cisplatin resistance in ovarian
cancer cells. Furthermore, cisplatin-resistant SKOV-3 [47]
and OVCAR-4 [44] cells express both IGF-I and the
IGF-IR [48].
Conclusions
Our results provide strong evidence for an essential role
for the IGF-IR signaling pathway mediating cisplatin re-
sistance in ovarian cancer. This study is the first study to
use primary clinical tumor material to provide a novelcomprehensive insight into the relation between the
IGF-1R signaling pathway and EOC tumorigenesis.
IGF-1R is overexpressed in EOC and, acting in an auto-
crine way, can influence tumor cell growth, proliferation
and apoptosis. These preclinical studies also provide the
framework for future clinical evaluation of IGF-1R AS to
treat EOC, either as a monotherapy or in combination
with cisplatin, and holds potential to advance the develop-
ment of therapies designed to overcome cisplatin resist-
ance. To realize the potential of our findings to benefit
ovarian cancer patients, it will be necessary to validate
these results in a clinical study. We envision that the re-
sults of this study will translate into the clinic and aid the
development of novel therapies targeting the IGF-IR path-
ways in ovarian cancer.
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